US pharmaceutical giant, Pfizer, revealed that it exceeded its goal of manufacturing 3 billion doses of Comirnaty, the Pfizer-BioNTech COVID-19 vaccine, in 2021.
The company, reportedly, also increased its 2022 revenue guidance for Comirnaty, reflecting that doses are expected to be delivered under supply contracts signed as of late January.
OERLive learns that Pfizer, in its issued fiscal guidance for the coming year, which if achieved, will represent the highest level of annual revenues in its history.
The company, in its long-term expectations for COVID-19, said that the virus would be able to mutate often, making it ‘difficult to stay ahead’, before adding that people can be reinfected by the same of different strains over time.
“Our scientists continue to monitor the SARS-CoV-2 virus and believe it is unlikely to be fully eradicated in the foreseeable future,” Pfizer stated.
Despite its revelation, Pfizer stock (NYSE: PFE) had dropped US$2.83 today [February 8] over its closing of US$53.21 on Monday [February 7]. Experts have pegged the drop to the drug maker missing forecasts, despite its fourth-quarter profit that beat expectations and doubled revenues.
Moreover, the company’s full-year outlook reportedly oversells analyst projections. Pfizer’s net income jumped to US$3.39bn, or 59 cents a share, from US$847mn, or 15 cents a share when compared with fiscal outcomes from 2021.
